La revascularización incompleta se asocia a mortalidad en el TAVI

Low Risk Patients: TAVR with Self-Expanding Valves Offers Similar Outcomes to Surgery Based on a Bayesian Analysis?

When compared against surgical valve replacement (SAVR) transcatheter aortic valve replacement (TAVR) has shown benefits across different risk groups, not only in events as death and stroke, but also in quality of life (especially in the first months post procedure) and improved symptoms.  However, a catch-up phenomenon was observed in low-risk patients between the first<a href="https://solaci.org/en/2022/03/17/low-risk-patients-tavr-with-self-expanding-valves-offers-similar-outcomes-to-surgery-based-on-a-bayesian-analysis/" title="Read more" >...</a>

Balancear el riesgo de sangrado vs trombótico para definir el tiempo de doble antiagregación

Acute Coronary Syndrome: What Is Safer, Antiaggregant Monotherapy or De-Escalation?

For several years it has been shown that 12-month dual antiplatelet therapy (DAPT) is mandatory for patients undergoing left main PCI for acute coronary syndrome (ACS). However, though this strategy does reduce thrombotic events and mortality, it also causes undesirable bleeding events followed by hospitalization and antiaggregation interruption for a period of time.  A feasible<a href="https://solaci.org/en/2022/03/09/acute-coronary-syndrome-what-is-safer-antiaggregant-monotherapy-or-de-escalation/" title="Read more" >...</a>

COMPASS: un nuevo lugar para el rivaroxaban en cardiopatía isquémica crónica

Cangrelor: Additional Research Findings Not Translating into Clinical Practice

The potent and fast endovenous platelet inhibition provided by Cangrelor reduces ischemic events early in the course of acute coronary syndrome. However, and despite mounting evidence, the drug is not reaching the clinical practice.   This is a sub-analysis of the CHAMPION PHOENIX, which sought the timing, number and type of early events that could be<a href="https://solaci.org/en/2022/01/27/cangrelor-additional-research-findings-not-translating-into-clinical-practice/" title="Read more" >...</a>

Escándalo con los resultados del EXCEL que hicieron “caer” las últimas guías

Clnical Practice Dissociated from Study Outcomes: Bad News for Our Patients?

Differences in patient characteristics, changes in treatment algorithms, and advances in device technology, together or separately, might limit the applicability of older randomized trials to contemporary clinical practice. In this case, we look at patients and devices used in the contemporary clinical practice vs. those in the EXTEND DAPT. These differences were associated with attenuated<a href="https://solaci.org/en/2022/01/25/clnical-practice-dissociated-from-study-outcomes-bad-news-for-our-patients/" title="Read more" >...</a>

Fentanilo en la angioplatia: ¿Cuál es el precio de un mayor confort en el procedimiento?

TICO: Age Impacts the Effect of Antiplatelet Monotherapy

The higher the age, the greater the benefit of ticagrelor monotherapy vs. dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome. This post hoc sub-analysis of the TICO study goes along the same lines as the TWILIGHT study (which we recently discussed), given that age is the most common reason for considering that a<a href="https://solaci.org/en/2022/01/11/tico-age-impacts-the-effect-of-antiplatelet-monotherapy/" title="Read more" >...</a>

The Most Read Articles of 2021: COVID-19

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on COVID-19. Follow us to keep up to date. The Most Read Articles of 2021: COVID-19 01- Efficacy of the Sinopharm Vaccine Against COVID-19 Vaccines developed with two different inactivated strains of SARS-CoV-2 (Sinopharm) significantly reduced<a href="https://solaci.org/en/2021/12/27/the-most-read-articles-of-2021-covid-19/" title="Read more" >...</a>

Bifurcación de tronco de coronaria distal: cantidad de stents

Provisional vs Dual Stenting in Left Main: An Endless Discussion?

True left main stem bifurcation patients have shown fewer adverse events with stepwise provisional stenting vs systematic dual stenting as first strategy, even though the difference was not significant. Usually, for any other vessel, the preferred technique is provisional stenting. However, when it comes to the left main, there is a randomized, dedicated, well designed<a href="https://solaci.org/en/2021/11/30/provisional-vs-dual-stenting-in-left-main-an-endless-discussion/" title="Read more" >...</a>

TCT 2021 | STOPDAPT-2 y MASTER-DAPT: la discusión continúa del ESC al TCT

TCT 2021 | STOPDAPT-2 and MASTER-DAPT: The Conversation Continues from ESC to TCT

Research on short-term dual antiplatelet therapy (DAPT) is still controversial. These discussions, however, seem to lead to the consensus that beyond the “category” of bleeding or ischemic risk, what is most important is a decision tailored to the patient being treated. DAPT duration should be individual, instead of standardized by a risk score. In the<a href="https://solaci.org/en/2021/11/12/tct-2021-stopdapt-2-and-master-dapt-the-conversation-continues-from-esc-to-tct-2/" title="Read more" >...</a>

TCT 2021 | STOPDAPT-2 and MASTER-DAPT: The Conversation Continues from ESC to TCT

Research on short-term dual antiplatelet therapy (DAPT) is still controversial. These discussions, however, seem to lead to the consensus that beyond the “category” of bleeding or ischemic risk, what is most important is a decision tailored to the patient being treated. DAPT duration should be individual, instead of standardized by a risk score. In the<a href="https://solaci.org/en/2021/11/12/tct-2021-stopdapt-2-and-master-dapt-the-conversation-continues-from-esc-to-tct/" title="Read more" >...</a>

STOPDAPT-2 ACS: One-Month DAPT NOT Enough in acute patients

One-month dual antiplatelet therapy (DAPT) in patients undergoing acute coronary syndrome (ACS) did not reach the safety and efficacy results observed in the general population of the original trial STOPDAPT-2. The STOPDAPT-2 ACS compared one-month DAPT followed by clopidogrel monotherapy for one year vs. one-year DAPT after PCI.  Initially, the study enrolled mostly stable patients<a href="https://solaci.org/en/2021/10/07/stopdapt-2-acs-one-month-dapt-not-enough-in-acute-patients/" title="Read more" >...</a>

thrombosis